Vasamed Inc
Vasamed, Inc. designs, licenses, manufactures, and distributes products, software, and services for assessing and managing hemodynamic health in the United States. It offers SensiLase PAD-IQ, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation for Doppler-obtained pressures; and Wound Imaging & SmartDraw wound measurement systems. The company also … Read more
Vasamed Inc (VSMD) - Net Assets
Latest net assets as of June 2009: $-2.10 Million USD
Based on the latest financial reports, Vasamed Inc (VSMD) has net assets worth $-2.10 Million USD as of June 2009.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.30 Million) and total liabilities ($3.40 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.10 Million |
| % of Total Assets | -160.99% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -135.85% |
| Growth Volatility | 206.41 |
Vasamed Inc - Net Assets Trend (1996–2008)
This chart illustrates how Vasamed Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vasamed Inc (1996–2008)
The table below shows the annual net assets of Vasamed Inc from 1996 to 2008.
| Year | Net Assets | Change |
|---|---|---|
| 2008-12-31 | $-1.20 Million | -189.52% |
| 2007-12-31 | $1.34 Million | +142.01% |
| 2006-12-31 | $-3.20 Million | -637.43% |
| 2005-12-31 | $594.94K | +116.10% |
| 2004-12-31 | $-3.69 Million | -440.76% |
| 2003-12-31 | $1.08 Million | +462.05% |
| 2002-12-31 | $-299.50K | -54.86% |
| 2001-12-31 | $-193.39K | -119.49% |
| 2000-12-31 | $992.30K | -70.42% |
| 1999-12-31 | $3.35 Million | -69.50% |
| 1998-12-31 | $11.00 Million | -45.54% |
| 1997-12-31 | $20.20 Million | -34.84% |
| 1996-12-31 | $31.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vasamed Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7221524300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2008)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $80.11K | % |
| Other Components | $91.43 Million | % |
| Total Equity | $-15.91 Million | 100.00% |
Vasamed Inc Competitors by Market Cap
The table below lists competitors of Vasamed Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Interact-TV Inc
PINK:ITVI
|
$0.93 |
|
LEEP Inc
PINK:LPPI
|
$0.93 |
|
Transtech Industries Inc
PINK:TRTI
|
$0.93 |
|
Gritstone bio, Inc.
NASDAQ:GRTSQ
|
$0.93 |
|
EcoLogix Resource Group Inc
PINK:EXRG
|
$0.93 |
|
Kinbasha Gaming International Inc
PINK:KNBA
|
$0.93 |
|
Café Serendipity Holdings Inc
PINK:CAFS
|
$0.93 |
|
Southcorp Capital Inc
PINK:STHC
|
$0.93 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vasamed Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2007 to 2008, total equity changed from -13,269,451 to -15,907,312, a change of -2,637,861.
- Net loss of 2,924,847 reduced equity.
- Other factors increased equity by 286,986.
Equity Change Factors (2007 to 2008)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.92 Million | -18.39% |
| Other Changes | $286.99K | +1.8% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Vasamed Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $23.79 | $0.00 | x |
| 1997-12-31 | $14.44 | $0.00 | x |
| 1998-12-31 | $7.48 | $0.00 | x |
| 1999-12-31 | $2.27 | $0.00 | x |
| 2000-12-31 | $0.66 | $0.00 | x |
| 2001-12-31 | $-0.13 | $0.00 | x |
| 2002-12-31 | $-0.11 | $0.00 | x |
| 2003-12-31 | $0.34 | $0.00 | x |
| 2004-12-31 | $-1.06 | $0.00 | x |
| 2005-12-31 | $0.16 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vasamed Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -93.31%
- • Asset Turnover: 2.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-153.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -30.32% | -4700.00% | 0.01x | 1.05x | $-12.50 Million |
| 1997 | -55.94% | -11300.00% | 0.00x | 1.07x | $-13.32 Million |
| 1998 | -107.27% | -1180.00% | 0.08x | 1.15x | $-12.90 Million |
| 1999 | -232.07% | -5804.23% | 0.03x | 1.28x | $-8.12 Million |
| 2000 | -534.33% | -530217800.00% | 0.00x | 2.74x | $-5.40 Million |
| 2001 | 0.00% | -494.55% | 0.32x | 0.00x | $-3.38 Million |
| 2002 | 0.00% | -117.63% | 0.60x | 0.00x | $-1.82 Million |
| 2003 | -210.37% | -107.40% | 1.25x | 1.56x | $-2.39 Million |
| 2004 | 0.00% | -600.66% | 1.05x | 0.00x | $-6.05 Million |
| 2005 | -821.62% | -352.61% | 0.87x | 2.69x | $-4.95 Million |
| 2006 | 0.00% | -318.41% | 0.79x | 0.00x | $-4.62 Million |
| 2007 | 0.00% | -180.03% | 1.67x | 0.00x | $-4.30 Million |
| 2008 | 0.00% | -93.31% | 2.01x | 0.00x | $-1.33 Million |
Industry Comparison
This section compares Vasamed Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vasamed Inc (VSMD) | $-2.10 Million | -30.32% | N/A | $0.93 |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |